PeptideSearch

KPV

Animal studies only

Get notified when the evidence changes.

Almost all the research is in animals. We do not know if the same thing happens in people.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-07-23

Also called Lysine-Proline-Valine / alpha-MSH 11-13

A three-piece fragment of a natural hormone. Studied for calming inflammation in the gut and skin.

Official status: Recommended, pending FDA rulemaking · Checked 2026-07-23

Can a doctor prescribe this?

Small pharmacy (503A)
An FDA panel said yes — nothing has changed yet
Large outsourcing facility (503B)
Never put forward to FDA

An FDA advisory panel voted 8-6 in favor in July 2026, but the rule isn't final. That usually takes a year or more.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

What FDA actually looked at

FDA reviewed this peptide for Wound healing and inflammatory conditions. That is a narrower question than the uses this peptide is usually marketed for.

What happens next

FDA has not said whether it will move KPV into Category 1 while it decides, and has not started formal rulemaking.

Without a Category 1 placement, nothing changes for pharmacies no matter how the vote went.

The July 2026 vote covered the 503A list only. No 503B review has been scheduled.

503B is the pathway that would allow large-scale supply. It has not moved.

Lab suppliers we list: 14

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 23 July 2026503A

    FDA proposed that KPV NOT be included on the 503A Bulks List. FDA reported no human exposure data for KPV.

    FDA briefing documentnot yet verified against primary source

  2. 23 July 2026503A

    The committee voted 8-6 with one abstention to recommend KPV for the 503A Bulks List, against FDA staff's recommendation. Advisory only.

    8–6, 1 abstained

    Press reportnot yet verified against primary source

  3. 16 April 2026503A

    FDA published a Federal Register notice announcing a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 at the White Oak campus, to consider seven peptides for the 503A Bulks List.

    Federal Registernot yet verified against primary source

We'll email you when a new study, trial or status change lands for KPV. Unsubscribe in one click.